Increased antiviral activity of microscale-purified HuIFNα8 (human interferon α8) over HuIFNα2b in Hep-2 cells challenged with Mengo virus

2007 ◽  
Vol 48 (3) ◽  
pp. 159 ◽  
Author(s):  
Alejandro Miranda Ariza ◽  
Julio César Sánchez García ◽  
Alexis Musacchio Lasa ◽  
Luis Javier González ◽  
Vladimir Besada Perez
1997 ◽  
Vol 273 (4) ◽  
pp. C1225-C1232 ◽  
Author(s):  
Hung-Yun Lin ◽  
Paul M. Yen ◽  
Faith B. Davis ◽  
Paul J. Davis

We have studied the prenuclear signal transduction pathway by which thyroid hormone potentiates the antiviral activity of human interferon-γ (IFN-γ) in HeLa cells, which are deficient in thyroid hormone receptor (TR). The action of thyroid hormone was compared with that of milrinone, which has structural homologies with thyroid hormone.l-Thyroxine (T4), 3,5,3′-l-triiodothyronine (T3), and milrinone enhanced the antiviral activity of IFN-γ up to 100-fold, a potentiation blocked by cycloheximide. The 5′-deiodinase inhibitor 6- n-propyl-2-thiouracil did not block the T4 effect. 3,3′,5,5′-Tetraiodothyroacetic acid prevented the effect of T4 but not of milrinone. The effects of T4 and milrinone were blocked by inhibitors of protein kinases C (PKC) and A (PKA) and restored by PKC and PKA agonists; only the effect of T4 was blocked by genistein, a tyrosine kinase inhibitor. In separate models, milrinone was shown not to interact with nuclear TR-β. T4 potentiation of the antiviral activity of IFN-γ requires PKC, PKA, and tyrosine kinase activities but not traditional TR.


FEBS Letters ◽  
1989 ◽  
Vol 249 (2) ◽  
pp. 257-260 ◽  
Author(s):  
György Premecz ◽  
Andrea Markovits ◽  
György Bagi ◽  
Tibor Farkas ◽  
István Földes

1988 ◽  
Vol 8 (6) ◽  
pp. 779-782 ◽  
Author(s):  
M.W. BEILHARZ ◽  
M.J. TYMMS ◽  
P.J. CHAMBERS ◽  
B. McINNES ◽  
P.M. PITHA-ROWE ◽  
...  

2005 ◽  
Vol 86 (6) ◽  
pp. 1589-1596 ◽  
Author(s):  
Nathan W. Bartlett ◽  
Karen Buttigieg ◽  
Sergei V. Kotenko ◽  
Geoffrey L. Smith

Human interferon lambdas (IFN-λs) (type III IFNs) exhibit antiviral activity in vitro by binding to a receptor complex distinct from that used by type I and type II IFNs, and subsequent signalling through the Janus kinase signal transducers and activators of transcription (STAT) pathway. However, evidence for a function of type III IFNs during virus infection in vivo is lacking. Here, the expression of murine IFN-λs by recombinant vaccinia virus (VACV) is described and these proteins are shown to have potent antiviral activity in vivo. VACV expressing murine IFN-λ2 (vIFN-λ2) and IFN-λ3 (vIFN-λ3) showed normal growth in tissue culture and expressed N-glycosylated IFN-λ in infected cell extracts and culture supernatants. The role that murine IFN-λs play during virus infection was assessed in two different mouse models. vIFN-λ2 and vIFN-λ3 were avirulent for mice infected intranasally and induced no signs of illness or weight loss, in contrast to control viruses. Attenuation of vIFN-λ2 was associated with increases in lymphocytes in bronchial alveolar lavages and CD4+ T cells in total-lung lymphocyte preparations. In addition, vIFN-λ2 was cleared more rapidly from infected lungs and, in contrast to control viruses, did not disseminate to the brain. Expression of IFN-λ2 also attenuated VACV in an intradermal-infection model, characterized by a delay in lesion onset and reduced lesion size. Thus, by characterizing murine IFN-λs within a mouse infection model, the potent antiviral and immunostimulatory activity of IFN-λs in response to poxvirus infection has been demonstrated.


2012 ◽  
Vol 46 (5) ◽  
pp. 285-290 ◽  
Author(s):  
N. A. Matvieieva ◽  
Yu. I. Kudryavets ◽  
A. A. Likhova ◽  
A. M. Shakhovskij ◽  
N. A. Bezdenezhnykh ◽  
...  

1980 ◽  
Vol 30 (2) ◽  
pp. 513-522
Author(s):  
H Heremans ◽  
A Billiau ◽  
P De Somer

In mice given single intraperitoneal doses of interferon, serum interferon levels peaked at 1 h postinjection and were reduced to zero at about 8 h. The interferon concentrations in spleen, liver, and lungs were about 100-fold higher than could be expected from the amount of serum contained in these organs. In the brain only low levels of antiviral activity were detected. In mice infected intraperitoneally with Mengo virus, viral replication in the brain occurred around day 4 and was accompanied by the appearance of large amounts of interferon (approximately 10(3.25) U/g). This was preceded, however, by viral replication in the spleen and by the appearance of modest amounts of interferon in spleen and serum. In these mice protection could be obtained with relatively small doses of interferon, provided protection could be obtained with relatively small doses of interferon, provided they were given before the time of maximal levels of endogenous serum interferon. In mice infected intranasally with vesicular stomatitis virus, virus replication in the brain started within 24 to 48 h and increased with time; also, small amounts of interferon (10(2) to 10(2.5) U/g) were already detectable on days 1 and 2. The major peak of virus replication in the brain occurred on days 5 to 6 and was accompanied by the appearance of large amounts of interferon (approximately 10(3.25) U/g). In this model early treatment with interferon also provided protection, but only if given in larger doses than in the Mengo virus system. Athymic (nu/nu) mice developed a chronic systemic infection when inoculated with a demotropic strain of vaccinia virus. No interferon was detected in sera, livers, spleens, or lungs of these animals; some mice had low levels of interferon-like antiviral activity in the brain, but no attempt was made to characterize this material. Daily administration of large doses of interferon failed to exert an effect on the development of this chronic disease. Yet, normal (NMRI) mice were protected against acute infection with dermotropic or neurotropic strains of vaccinia virus, and athymic mice were partially protected against acute lethal infection with neurotropic vaccinia virus.


2014 ◽  
Vol 108 ◽  
pp. 142-147 ◽  
Author(s):  
Weili Yu ◽  
Changming Yu ◽  
Ling Wu ◽  
Ting Fang ◽  
Rui Qiu ◽  
...  

1976 ◽  
Vol 251 (6) ◽  
pp. 1659-1662 ◽  
Author(s):  
S Bose ◽  
D Gurari-Rotman ◽  
U T Ruegg ◽  
L Corley ◽  
C B Anfinsen

Sign in / Sign up

Export Citation Format

Share Document